Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Response Genetics's Debt-to-Equity or its related term are showing as below:
RGDXQ's Debt-to-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.33 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Response Genetics Debt-to-Equity Related Terms
Response Genetics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Response Genetics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGDXQ vs PSID, GBSN, ETAH: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Response Genetics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Response Genetics Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Response Genetics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Response Genetics (RGDXQ) has a Debt-to-Equity of 0.19 as of Dec. 2015. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Response Genetics and its competitors.
Is Response Genetics' Debt-to-Equity too high?
Response Genetics' current Debt-to-Equity is 0.19. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Response Genetics' value of 0.19 is 42.4% below this industry median.
How does Response Genetics' Debt-to-Equity compare to PSID and GBSN?
Response Genetics' Debt-to-Equity of 0.19 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Debt-to-Equity is 0.33. Response Genetics' value of 0.19 is 42.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Response Genetics's current Debt-to-Equity of 0.19 is 42.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Response Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Response Genetics's current Debt-to-Equity is 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Debt-to-Equity of 0.19. The current Debt-to-Equity is 0.19 and 42.4% below the Medical Diagnostics & Research industry median of 0.33. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Debt-to-Equity is 0.19 as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGDXQ has been successfully added to your 
